Matches in SemOpenAlex for { <https://semopenalex.org/work/W4244906110> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W4244906110 endingPage "2526" @default.
- W4244906110 startingPage "2526" @default.
- W4244906110 abstract "2526 Background: Vaccination with dendritic cell (DC)/tumor cell fusions can induce specific anti-tumor immunity in preclinical studies and has shown clinical activity. We report results of a fully enrolled, ongoing phase I/II study of electrofusion vaccine (EFV), comprised of allogeneic DCs (alloDC) and autologous tumor-derived cells administered subcutaneously to patients with Stage IV renal cell carcinoma (RCC). Methods: Tumors were processed and cryopreserved following acquisition from the primary or a metastatic site. Volunteer donor peripheral blood mononuclear cells were used to generate alloDC. At 6 week intervals, patients received up to 3 freshly prepared, irradiated EFV, within a constant dose range of 4 x 107 to 1 x 108 total cells. Study endpoints were safety, and tumor and immunologic response assessments. Results: Of the 30 enrolled patients, data are available on 21; 19 of the 21 were eligible for vaccination. The median age is 58 years (12 M, 9 F); mean number of metastatic sites is 2.4. Fifteen patients received prior treatments, including high dose IL-2. The mean fusion efficiency for 50 vaccine preparations is 20.7%, as determined by cell coexpression of specific DC and tumor markers. The only serious adverse event (excessive intraoperative bleeding) considered related to the study occurred during a tumor acquisition procedure. Adverse events assessed by the investigators as related to EFV and occurring in more than 1 patient were injection site reactions (n=5), fatigue (n=3) and coughing (n=3), all Common Toxicity Criteria grade I or II. Tumor responses to date (9 patients) are 1 partial response, 3 stable disease. Complete analyses of safety, immunologic reactivity (autologous tumor-induced delayed-type hypersensitivity and intracellular interferon γ production) and tumor response assessments will be presented. Conclusions: These interim data suggest a vaccination strategy employing alloDC electrofused with tumor-derived cells in patients with Stage IV RCC is feasible, well-tolerated and may show evidence of tumor response. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Dana-Farber Cancer Institute; Genzyme Corp. Genzyme Corp. Genzyme Corp. Genzyme" @default.
- W4244906110 created "2022-05-12" @default.
- W4244906110 creator A5016502031 @default.
- W4244906110 creator A5019068922 @default.
- W4244906110 creator A5028587355 @default.
- W4244906110 creator A5050649350 @default.
- W4244906110 creator A5052641327 @default.
- W4244906110 creator A5056766924 @default.
- W4244906110 creator A5063621818 @default.
- W4244906110 creator A5066583447 @default.
- W4244906110 creator A5072612101 @default.
- W4244906110 creator A5082466279 @default.
- W4244906110 date "2004-07-15" @default.
- W4244906110 modified "2023-09-26" @default.
- W4244906110 title "Interim safety and efficacy results from a phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma" @default.
- W4244906110 doi "https://doi.org/10.1200/jco.2004.22.14_suppl.2526" @default.
- W4244906110 hasPublicationYear "2004" @default.
- W4244906110 type Work @default.
- W4244906110 citedByCount "3" @default.
- W4244906110 crossrefType "journal-article" @default.
- W4244906110 hasAuthorship W4244906110A5016502031 @default.
- W4244906110 hasAuthorship W4244906110A5019068922 @default.
- W4244906110 hasAuthorship W4244906110A5028587355 @default.
- W4244906110 hasAuthorship W4244906110A5050649350 @default.
- W4244906110 hasAuthorship W4244906110A5052641327 @default.
- W4244906110 hasAuthorship W4244906110A5056766924 @default.
- W4244906110 hasAuthorship W4244906110A5063621818 @default.
- W4244906110 hasAuthorship W4244906110A5066583447 @default.
- W4244906110 hasAuthorship W4244906110A5072612101 @default.
- W4244906110 hasAuthorship W4244906110A5082466279 @default.
- W4244906110 hasConcept C126322002 @default.
- W4244906110 hasConcept C137061746 @default.
- W4244906110 hasConcept C141071460 @default.
- W4244906110 hasConcept C143998085 @default.
- W4244906110 hasConcept C185592680 @default.
- W4244906110 hasConcept C197934379 @default.
- W4244906110 hasConcept C202751555 @default.
- W4244906110 hasConcept C203014093 @default.
- W4244906110 hasConcept C22070199 @default.
- W4244906110 hasConcept C2777472916 @default.
- W4244906110 hasConcept C2778170410 @default.
- W4244906110 hasConcept C535046627 @default.
- W4244906110 hasConcept C55493867 @default.
- W4244906110 hasConcept C61943457 @default.
- W4244906110 hasConcept C71924100 @default.
- W4244906110 hasConcept C8891405 @default.
- W4244906110 hasConcept C90924648 @default.
- W4244906110 hasConceptScore W4244906110C126322002 @default.
- W4244906110 hasConceptScore W4244906110C137061746 @default.
- W4244906110 hasConceptScore W4244906110C141071460 @default.
- W4244906110 hasConceptScore W4244906110C143998085 @default.
- W4244906110 hasConceptScore W4244906110C185592680 @default.
- W4244906110 hasConceptScore W4244906110C197934379 @default.
- W4244906110 hasConceptScore W4244906110C202751555 @default.
- W4244906110 hasConceptScore W4244906110C203014093 @default.
- W4244906110 hasConceptScore W4244906110C22070199 @default.
- W4244906110 hasConceptScore W4244906110C2777472916 @default.
- W4244906110 hasConceptScore W4244906110C2778170410 @default.
- W4244906110 hasConceptScore W4244906110C535046627 @default.
- W4244906110 hasConceptScore W4244906110C55493867 @default.
- W4244906110 hasConceptScore W4244906110C61943457 @default.
- W4244906110 hasConceptScore W4244906110C71924100 @default.
- W4244906110 hasConceptScore W4244906110C8891405 @default.
- W4244906110 hasConceptScore W4244906110C90924648 @default.
- W4244906110 hasIssue "14_suppl" @default.
- W4244906110 hasLocation W42449061101 @default.
- W4244906110 hasOpenAccess W4244906110 @default.
- W4244906110 hasPrimaryLocation W42449061101 @default.
- W4244906110 hasRelatedWork W1505169546 @default.
- W4244906110 hasRelatedWork W1964804566 @default.
- W4244906110 hasRelatedWork W2002120878 @default.
- W4244906110 hasRelatedWork W2046249728 @default.
- W4244906110 hasRelatedWork W2047967234 @default.
- W4244906110 hasRelatedWork W2439875401 @default.
- W4244906110 hasRelatedWork W2518309888 @default.
- W4244906110 hasRelatedWork W2751942428 @default.
- W4244906110 hasRelatedWork W4311749156 @default.
- W4244906110 hasRelatedWork W1670642307 @default.
- W4244906110 hasVolume "22" @default.
- W4244906110 isParatext "false" @default.
- W4244906110 isRetracted "false" @default.
- W4244906110 workType "article" @default.